Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs Manhattan Associates Inc (MANH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs Manhattan Associates Inc — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $299.18 (market cap $8.04B), while Manhattan Associates Inc trades at $161.34 (market cap $9.38B). The key difference: Manhattan Associates Inc is the larger of the two by market cap, and Bio-Rad Laboratories, Inc. Class A Common Stock is trading nearer its 52-week high, Manhattan Associates Inc nearer its low. Which is the better fit depends on your goals.
| BIO | MANH | |
|---|---|---|
Market Cap | $8.04B | $9.38B |
Sector | Health | Technology |
52-Week High | $339.75 | $227.94 |
52-Week Low | $241.71 | $120.88 |
Enterprise Value | $7.85B | $9.21B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIO trades at $297.58, up 0.5% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $305. The stock shows strong profitability with a 51.87% gross margin and positive net income of $760M in 2025, though recent quarters have seen EPS misses. Cash flow from operations remains robust at $532M, supporting financial stability.
Outlook is cautiously optimistic with analyst support, but risks include earnings volatility and high P/E valuation. The company's return to profitability and solid balance sheet provide a foundation for growth, though investors should monitor execution against future earnings expectations and competitive pressures in the biotech sector.
MANH trades at $158.31, up 2.2% today, with a bullish technical outlook supported by moving averages and strong quarterly EPS beats. The company maintains robust profitability with a 19.68% net margin and 96.24% ROE, though valuation multiples like P/E of 44.43 are elevated. Recent news highlights ongoing legal investigations but also cloud growth initiatives.
Outlook remains positive with a $192.80 analyst price target implying 22% upside, but risks include high valuation sensitivity, legal overhang from fiduciary investigations, and competitive pressures in supply chain software. Earnings momentum and institutional support provide near-term catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About Manhattan Associates Inc
Manhattan Associates, Inc. is a global leader in supply chain and omnichannel commerce software. The company provides a comprehensive suite of cloud-based and on-premise solutions for warehouse management (WMS), transportation management (TMS), and order management (OMS). MANH's technology helps retailers, wholesalers, and manufacturers manage inventory, optimize logistics, and unify the shopping experience across physical and digital channels.
Read more on MANH →
